It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in visual acuity (logMAR) ‐ 12 months (negative is better) compared with macular laser (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with macular laser (low certainty).
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in retinal thickness (micron) (negative is better) compared with macular laser (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher cataract progression ‐ 9 to 24 months compared with macular laser (moderate certainty).
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher use of IOP‐lowering medications ‐ 9 to 24 months compared with macular laser (moderate certainty).
Intravitreal triamcinolone acetonide injection 4 mg showed no clear difference in surgery for glaucoma ‐ 9 to 24 months compared with macular laser (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes change in central retinal thickness (micron) ‐ 12 months (negative… compared with antiVEGF (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes live birth (or ongoing pregnancy) compared with no intervention (very low certainty).
It is very uncertain whether intraovarian injection of autologous platelet‐rich plasma changes ongoing pregnancy compared with no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intraovarian injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes miscarriage compared with no intervention (very low certainty).
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention (very low certainty).
It is very uncertain whether intrauterine injection of autologous platelet‐rich plasma changes adverse events: ectopic pregnancy compared with no intervention (very low certainty).